Significance of Midkine Signaling in Women’s Cancers: Novel Biomarker and Therapeutic Target
International Journal of Molecular Sciences · 17.05.2025 · 26 (10) · 4809
DOI: 10.3390/ijms26104809 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.05.2025. Verfasst von Emily J Aller und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA. Hauptthemen laut MEDLINE: Midkine, Signal Transduction, Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, BLRD VA.
Abstract (Originalsprache)
Midkine (MDK) is a multifunctional protein that is secreted into the extracellular space. It functions as a cytokine or growth factor, modulating a variety of signaling pathways implicated in angiogenesis, antitumor immunity, metastasis, and therapy resistance. MDK overexpression has been documented in a variety of cancers, including those that affect women. MDK mediates its effects through activation of key signaling pathways such as MAPK/ERK, PI3K/AKT, and STAT3, which are pivotal for cell cycle progression, survival, and maintenance of stemness. Obesity and estrogen signaling, a known critical driver of women’s cancer, further elevate the levels of MDK. MDK’s effects are mediated by a variety of membrane receptors, such as integrins, protein tyrosine phosphatase ζ (PTPζ), anaplastic lymphoma kinase (ALK), and neurogenic locus notch homolog protein 2 (Notch2). Recently published studies have indicated that MDK is a potential therapeutic target and a biomarker for the progression of women’s cancer. In this review, we have provided a concise summary of the most recent papers that have examined the potential biomarker and therapeutic utility of MDK signaling in women’s cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
- Mays Cancer Canter, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
- Audie L. Murphy Division, South Texas Veterans Health Care System, San Antonio, TX 78229, USA.
ORCID-Profile: Emily J Aller, Hareesh B Nair, Ratna K Vadlamudi, Suryavathi Viswanadhapalli
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- BLRD VA
- NIH HHS
- STX-MSTP–NIH
Zitieren
APA
Aller, E. J., Nair, H. B., Vadlamudi, R. K., & Viswanadhapalli, S. (2025). Significance of Midkine Signaling in Women’s Cancers: Novel Biomarker and Therapeutic Target. International Journal of Molecular Sciences, 26(10), 4809. https://doi.org/10.3390/ijms26104809
Vancouver
Aller EJ, Nair HB, Vadlamudi RK, Viswanadhapalli S. Significance of Midkine Signaling in Women’s Cancers: Novel Biomarker and Therapeutic Target. International Journal of Molecular Sciences. 2025;26(10):4809. doi:10.3390/ijms26104809
BibTeX
@article{Aller2025,
author = {Aller, Emily J and Nair, Hareesh B and Vadlamudi, Ratna K and Viswanadhapalli, Suryavathi},
title = {Significance of Midkine Signaling in Women’s Cancers: Novel Biomarker and Therapeutic Target},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {10},
pages = {4809},
doi = {10.3390/ijms26104809}
}
EUVIMED